PharmD Signal

Deep dives, evidence grades, and clinical tools, all in one place.

Nivolumab Plus Chemotherapy in Gastric Cancer Patients Aged 75 and Older: Real-World Feasibility

nivolumabimmune checkpoint inhibitorS-1capecitabineoxaliplatinfluorouracilgastric cancerolder adultsgeriatric oncologyretrospective cohortreal-world evidencedose reductionimmune-related adverse eventsfirst-line therapyHER2-negative Oncology
Also in Geriatrics

Background Information

Can older gastric cancer patients benefit from nivolumab plus chemotherapy?

Older patients are underrepresented in clinical trials of immune checkpoint inhibitors for gastric cancer. For patients aged ≥ 75 years, median progression-free survival was 5.6 months, similar to younger patients (P = 0.779). Overall survival was 13.3 months (P = 0.852). Findings suggest nivolumab plus chemotherapy is feasible for older patients, but results should be cautiously interpreted due to the small sample size. Nivolumab plus chemotherapy may be a viable option for gastric cancer in patients aged 75 or older.

📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.

Authors: Yoshimatsu M, Morita S, Ueta Y, Mise M, Inoue N, Ochiai T, Takise S, Fujita J, Muroi H, Nakagawa M, Nakajima M, Yamaguchi S, Kojima K

Citation: Yoshimatsu M, Morita S, Ueta Y, et al. Clinical outcomes of first-line nivolumab plus chemotherapy in patients aged ≥ 75 years with unresectable advanced or recurrent gastric cancer: a retrospective study. World journal of surgical oncology. 2026;24(1). doi:10.1186/s12957-026-04525-x

Article Links: PubMed · Journal / DOI · Free Full Text (PMC)

🎓
Reviewed by a licensed pharmacist
Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.
Accurate and up-to-date information is our highest priority.
If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.
Thanks for the feedback!
🔒
Deep Analysis: Subscribers Only
Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.
Executive Summary
Study Design
Patient Population
Primary Outcomes
Secondary Outcomes & Safety Profile
Pharmacist Implications
Clinical Pearls
Limitations
Controversies & Evidence Gaps
Cost & Logistics
Founding member rate
$8/month. Cancel anytime.

One subscription unlocks this analysis and every other one we publish, plus Practice Signals, PDF reports, and GRADE evidence grades.

Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.
Or $79/year. Founding members keep this rate for as long as they stay subscribed. Cancel anytime from your Account page.